These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32496677)

  • 41. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J
    Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
    Hansmann G; Apitz C
    Heart; 2016 May; 102 Suppl 2():ii67-85. PubMed ID: 27053700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treating pulmonary hypertension in pediatrics.
    Lador F; Sekarski N; Beghetti M
    Expert Opin Pharmacother; 2015 Apr; 16(5):711-26. PubMed ID: 25665593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pulmonary arterial hypertension specific therapy: The old and the new.
    Zolty R
    Pharmacol Ther; 2020 Oct; 214():107576. PubMed ID: 32417272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis.
    Badiani B; Messori A
    Heart Lung Circ; 2016 Jan; 25(1):46-52. PubMed ID: 26233257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
    Humbert M; Kovacs G; Hoeper MM; Badagliacca R; Berger RMF; Brida M; Carlsen J; Coats AJS; Escribano-Subias P; Ferrari P; Ferreira DS; Ghofrani HA; Giannakoulas G; Kiely DG; Mayer E; Meszaros G; Nagavci B; Olsson KM; Pepke-Zaba J; Quint JK; Rådegran G; Simonneau G; Sitbon O; Tonia T; Toshner M; Vachiery JL; Vonk Noordegraaf A; Delcroix M; Rosenkranz S;
    Eur Heart J; 2022 Oct; 43(38):3618-3731. PubMed ID: 36017548
    [No Abstract]   [Full Text] [Related]  

  • 47. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges.
    Lajoie AC; Bonnet S; Provencher S
    Pulm Circ; 2017; 7(2):312-325. PubMed ID: 28597774
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.
    Zheng W; Wang Z; Jiang X; Zhao Q; Shen J
    J Med Chem; 2020 Dec; 63(24):15153-15186. PubMed ID: 33314936
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension.
    Schikowski EM; Swabe G; Chan SY; Magnani JW
    J Am Heart Assoc; 2022 Nov; 11(22):e026620. PubMed ID: 36370005
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of pulmonary arterial hypertension.
    McLaughlin VV; Shah SJ; Souza R; Humbert M
    J Am Coll Cardiol; 2015 May; 65(18):1976-97. PubMed ID: 25953750
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Medical treatment of pulmonary hypertension: what's new?].
    Richter MJ; Gall H; Tello K; Sommer N; Seeger W; Grimminger F; Ghofrani HA
    Internist (Berl); 2015 May; 56(5):573-82. PubMed ID: 25924799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
    Lammi MR; Mathai SC; Saketkoo LA; Domsic RT; Bojanowski C; Furst DE; Steen VD;
    Arthritis Rheumatol; 2016 Mar; 68(3):740-8. PubMed ID: 26479414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of Knowledge, Attitude, and Practice Patterns in Pulmonary Arterial Hypertension among Cardiologists and Pulmonologists: Evidence from Turkey.
    Günaydın FE; Belen E; Altın S; Demir AU; Güven G; Durmuş G
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893587
    [No Abstract]   [Full Text] [Related]  

  • 56. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
    Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
    Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current clinical management of pulmonary arterial hypertension.
    Zamanian RT; Kudelko KT; Sung YK; Perez VJ; Liu J; Spiekerkoetter E
    Circ Res; 2014 Jun; 115(1):131-147. PubMed ID: 24951763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
    Lan TH; Chen XL; Wu YS; Qiu HL; Li JZ; Ruan XM; Xu DP; Lin DQ
    Eur J Pharmacol; 2018 Jun; 829():102-111. PubMed ID: 29665366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.